New Guidance for General Practice to prescribe Mounjaro (tirzepatide)

As outlined in NICE guidelines, some people with obesity may be eligible to access tirzepatide (Mounjaro®), for weight loss purposes.

This will be introduced through a phased approach focused on those with the greatest clinical need. The number of people who are eligible will be small initially.

Eligibility is determined by BMI of 40 or more, or 37.5 for those from minority ethnic backgrounds, and with at least four of the following conditions:

type 2 diabetes

high blood pressure

heart and vascular disease

high cholesterol

obstructive sleep apnea

There will be a phased approach which is detailed below:

If you do not satisfy this criteria you will not be eligible.

There is very little funding available and we are still to receive further guidance from our ICB.